Advertisement

The Latest

The U.S. Food and Drug Administration sent AstraZeneca a Complete Response Letter, rejecting a new drug application for the company's Axanum, according to an AstraZeneca news release.

The survival and success of ASCs relies on recruiting physicians who can bring patients to the table, and having enough physicians and cases to keep ASCs profitable. But many ASCs are finding that recruiting new physicians to help the facility…

Advertisement